BRTX
BioRestorative Therapies, Inc. Common Stock (NV)
stockNASDAQ
biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient's damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.75 | 2026-10-12 | -13.71% | -4.068 |
| 1M | 2.69 | 2026-09-18 | -43.87% | 1.832 |
| 3M | 6.68 | 2026-07-17 | -77.40% | -0.206 |
| 6M | 5.27 | 2026-04-17 | -71.37% | 0.818 |
| 1Y | 31.70 | 2025-10-17 | -95.24% | 1.739 |
| 2Y | 33.30 | 2024-10-18 | -95.47% | — |
| 5Y | 360.00 | 2021-10-18 | -99.58% | 1.058 |
BioRestorative Therapies, Inc. Common Stock (NV) (NASDAQ:BRTX) stock price today is $1.51, and today's volume is 21,012. BRTX is up 3.425% today. The 30 day average volume is 34,864. BRTX market cap is $2.09M with 1.38M shares outstanding.